Glutaminolysis as a target for cancer therapy

Oncogene

Volumn 35, Issue 28, 2016, Pages 3619-3625

  Jin, L ^a   Alesi, G N ^a   Kang, S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOBICYCLO[2.2.1]HEPTANE 2 CARBOXYLIC ACID; 6 DIAZO 5 OXONORLEUCINE; ACETAMIDE DERIVATIVE; ACIVICIN; AMINOOXYACETIC ACID; ASPARTATE AMINOTRANSFERASE; AZASERINE; BENZYLSERINE; BIS 2 [ 5 PHENYLACETAMIDO 1,2,4 THIADIAZOL 2 YL]ETHYL SULFIDE; ENZYME; EPIGALLOCATECHIN GALLATE; GLUTAMATE DEHYDROGENASE; GLUTAMIC ACID; GLUTAMINASE; GLUTAMINE; GLUTAMINE TRANSPORTER; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEMBRANE PROTEIN; PURPURIN; RAPAMYCIN; SERINE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MOLECULAR LIBRARY;

AMINO ACID METABOLISM; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CELL PROLIFERATION; CRYSTAL STRUCTURE; ENZYME MODIFICATION; GENE TARGETING; GLUTAMINOLYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOLECULE; NEOPLASM; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN ACETYLATION; REVIEW; TUMOR GROWTH; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; NEOPLASMS; PATHOLOGY; THERAPEUTIC USE;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; GLUTAMINE; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; NEOPLASMS; SMALL MOLECULE LIBRARIES;

EID: 84978900742     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.447     Document Type: Review

References (91)

1. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134: 703-707.
2. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
3. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66: 8927-8930.
4. Frezza C, Gottlieb E. Mitochondria in cancer: not just innocent bystanders. Semin Cancer Biol 2009; 19: 4-11.
5. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010; 35: 427-433.
6. Medina MA. Glutamine and cancer. J Nutr 2001; 131: 2539S-2542S.
7. Reitzer LJ, Wice BM, Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 1979; 254: 2669-2676.
8. Lu W, Pelicano H, Huang P. Cancer metabolism: is glutamine sweeter than glucose? Cancer Cell 2010; 18: 199-200.
9. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007; 104: 19345-19350.
10. Wellen KE, Lu C, Mancuso A, Lemons JM, Ryczko M, Dennis JW et al. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev 2010; 24: 2784-2799.
11. Duran RV, Oppliger W, Robitaille AM, Heiserich L, Skendaj R, Gottlieb E et al. Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell 2012; 47: 349-358.
12. Jin L, Li D, Alesi GN, Fan J, Kang HB, Lu Z et al. Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. Cancer Cell 2015; 27: 257-270.
13. Zhang J, Fan J, Venneti S, Cross JR, Takagi T, Bhinder B et al. Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Mol Cell 2014; 56: 205-218.
14. Qing G, Li B, Vu A, Skuli N, Walton ZE, Liu X et al. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell 2012; 22: 631-644.
15. Eng CH, Yu K, Lucas J, White E, Abraham RT. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. Sci Signal 2010; 3ra31.
16. Medina MA, Sanchez-Jimenez F, Marquez J, Rodriguez Quesada A, Nunez de Castro I. Relevance of glutamine metabolism to tumor cell growth. Mol Cell Biochem 1992; 113: 1-15.
17. Kovacevic Z, McGivan JD. Mitochondrial metabolism of glutamine and glutamate and its physiological significance. Physiol Rev 1983; 63: 547-605.
18. Souba WW. Glutamine and cancer. Ann Surg 1993; 218: 715-728.
19. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010; 29: 313-324.
20. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest 2013; 123: 3678-3684.
21. Moreadith RW, Lehninger AL. The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme. J Biol Chem 1984; 259: 6215-6221.
22. Medina MA, Nunez de Castro I. Glutaminolysis and glycolysis interactions in proliferant cells. Int J Biochem 1990; 22: 681-683.
23. Dang CV. Glutaminolysis: supplying carbon or nitrogen or both for cancer cells? Cell Cycle 2010; 9: 3884-3886.
24. McKeehan WL. Glycolysis, glutaminolysis and cell proliferation. Cell Biol Int Rep 1982; 6: 635-650.
25. Newsholme EA, Crabtree B, Ardawi MS. Glutamine metabolism in lymphocytes: its biochemical, physiological and clinical importance. Q J Exp Physiol 1985; 70: 473-489.
26. Friday E, Oliver R 3rd, Welbourne T, Turturro F. Glutaminolysis and glycolysis regulation by troglitazone in breast cancer cells: relationship to mitochondrial membrane potential. J Cell Physiol 2011; 226: 511-519.
27. Mullen AR, Hu Z, Shi X, Jiang L, Boroughs LK, Kovacs Z et al. Oxidation of alphaketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell Rep 2014; 7: 1679-1690.
28. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2012; 481: 380-384.
29. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2012; 481: 385-388.
30. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009; 136: 521-534.
31. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 2013; 12: 931-947.
32. Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 2015; 27: 211-222.
33. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458: 762-765.
34. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013; 496: 101-105.
35. Adam J, Hatipoglu E, O'Flaherty L, Ternette N, Sahgal N, Lockstone H et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 2011; 20: 524-537.
36. Ooi A, Wong JC, Petillo D, Roossien D, Perrier-Trudova V, Whitten D et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 2011; 20: 511-523.
37. Lacey JM, Wilmore DW. Is glutamine a conditionally essential amino acid? Nutr Rev 1990; 48: 297-309.
38. Bhutia YD, Babu E, Ramachandran S, Ganapathy V. Amino acid transporters in cancer and their relevance to 'glutamine addiction': novel targets for the design of a new class of anticancer drugs. Cancer Res 2015; 75: 1782-1788.
39. Reynolds MR, Lane AN, Robertson B, Kemp S, Liu Y, Hill BG et al. Control of glutamine metabolism by the tumor suppressor Rb. Oncogene 2014; 33: 556-566.
40. Elorza A, Soro-Arnaiz I, Melendez-Rodriguez F, Rodriguez-Vaello V, Marsboom G, de Carcer G et al. HIF2alpha acts as an mTORC1 activator through the amino acid carrier SLC7A5. Mol Cell 2012; 48: 681-691.
41. Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M et al. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 2013; 122: 3521-3532.
42. Hassanein M, Hoeksema MD, Shiota M, Qian J, Harris BK, Chen H et al. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res 2013; 19: 560-570.
43. Hassanein M, Qian J, Hoeksema MD, Wang J, Jacobovitz M, Ji X et al. Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer. Int J Cancer 2015; 137: 1587-1597.
44. Wang Q, Beaumont KA, Otte NJ, Font J, Bailey CG, van Geldermalsen M et al. Targeting glutamine transport to suppress melanoma cell growth. Int J Cancer 2014; 135: 1060-1071.
45. Mates JM, Segura JA, Martin-Rufian M, Campos-Sandoval JA, Alonso FJ, Marquez J. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Curr Mol Med 2013; 13: 514-534.
46. Xiang Y, Stine ZE, Xia J, Lu Y, O'Connor RS, Altman BJ et al. Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J Clin Invest 2015; 125: 2293-2306.
47. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 2007; 178: 93-105.
48. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 2008; 105: 18782-18787.
49. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 2012; 15: 110-121.
50. Murphy TA, Dang CV, Young JD. Isotopically nonstationary 13C flux analysis of Myc-induced metabolic reprogramming in B-cells. Metab Eng 2013; 15: 206-217.
51. Csibi A, Lee G, Yoon SO, Tong H, Ilter D, Elia I et al. The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation. Curr Biol 2014; 24: 2274-2280.
52. Csibi A, Fendt SM, Li C, Poulogiannis G, Choo AY, Chapski DJ et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 2013; 153: 840-854.
53. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010; 18: 207-219.
54. Thangavelu K, Pan CQ, Karlberg T, Balaji G, Uttamchandani M, Suresh V et al. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. Proc Natl Acad Sci USA 2012; 109: 7705-7710.
55. Colombo SL, Palacios-Callender M, Frakich N, Carcamo S, Kovacs I, Tudzarova S et al. Molecular basis for the differential use of glucose and glutamine in cell proliferation as revealed by synchronized HeLa cells. Proc Natl Acad Sci USA 2011; 108: 21069-21074.
56. Moncada S, Higgs EA, Colombo SL. Fulfilling the metabolic requirements for cell proliferation. Biochem J 2012; 446: 1-7.
57. Robinson MM, McBryant SJ, Tsukamoto T, Rojas C, Ferraris DV, Hamilton SK et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J 2007; 406: 407-414.
58. Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther 2014; 13: 890-901.
59. Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Mates JM et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci USA 2011; 108: 8674-8679.
60. Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N et al. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J Clin Invest 2015; 125: 1591-1602.
61. Herranz D, Ambesi-Impiombato A, Sudderth J, Sanchez-Martin M, Belver L, Tosello V et al. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nat Med 2015; 21: 1182-1189.
62. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA 2010; 107: 7455-7460.
63. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci USA 2010; 107: 7461-7466.
64. Martin-Rufian M, Nascimento-Gomes R, Higuero A, Crisma AR, Campos-Sandoval JA, Gomez-Garcia MC et al. Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells. J Mol Med (Berl) 2014; 92: 277-290.
65. Xiang L, Xie G, Liu C, Zhou J, Chen J, Yu S et al. Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation. Biochim Biophys Acta 2013; 1833: 2996-3005.
66. Giacobbe A, Bongiorno-Borbone L, Bernassola F, Terrinoni A, Markert EK, Levine AJ et al. p63 regulates glutaminase 2 expression. Cell Cycle 2013; 12: 1395-1405.
67. Gao M, Monian P, Quadri N, Ramasamy R, Jiang X. Glutaminolysis and Transferrin regulate Ferroptosis. Mol Cell 2015; 59: 298-308.
68. Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 2009; 69: 7986-7993.
69. Plaitakis A, Latsoudis H, Spanaki C. The human GLUD2 glutamate dehydrogenase and its regulation in health and disease. Neurochem Int 2011; 59: 495-509.
70. Smith TJ, Stanley CA. Untangling the glutamate dehydrogenase allosteric nightmare. Trends Biochem Sci 2008; 33: 557-564.
71. Li C, Allen A, Kwagh J, Doliba NM, Qin W, Najafi H et al. Green tea polyphenols modulate insulin secretion by inhibiting glutamate dehydrogenase. J Biol Chem 2006; 281: 10214-10221.
72. Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 2006; 126: 941-954.
73. Stanley CA, Lieu YK, Hsu BY, Burlina AB, Greenberg CR, Hopwood NJ et al. Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med 1998; 338: 1352-1357.
74. Choo AY, Kim SG, Vander Heiden MG, Mahoney SJ, Vu H, Yoon SO et al. Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell 2010; 38: 487-499.
75. Lorin S, Tol MJ, Bauvy C, Strijland A, Pous C, Verhoeven AJ et al. Glutamate dehydrogenase contributes to leucine sensing in the regulation of autophagy. Autophagy 2013; 9: 850-860.
76. Chen R, Nishimura MC, Kharbanda S, Peale F, Deng Y, Daemen A et al. Hominoidspecific enzyme GLUD2 promotes growth of IDH1R132H glioma. Proc Natl Acad Sci USA 2014; 111: 14217-14222.
77. Yang H, Zhou L, Shi Q, Zhao Y, Lin H, Zhang M et al. SIRT3-dependent GOT2 acetylation status affects the malate-aspartate NADH shuttle activity and pancreatic tumor growth. EMBO J 2015; 34: 1110-1125.
78. Ahluwalia GS, Grem JL, Hao Z, Cooney DA. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol Ther 1990; 46: 243-271.
79. Elhammali A, Ippolito JE, Collins L, Crowley J, Marasa J, Piwnica-Worms D. A highthroughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. Cancer Discov 2014; 4: 828-839.
80. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012; 491: 364-373.
81. DeLaBarre B, Hurov J, Cianchetta G, Murray S, Dang L. Action at a distance: allostery and the development of drugs to target cancer cell metabolism. Chem Biol 2014; 21: 1143-1161.
82. Katt WP, Cerione RA. Glutaminase regulation in cancer cells: a druggable chain of events. Drug Discov Today 2014; 19: 450-457.
83. Shukla K, Ferraris DV, Thomas AG, Stathis M, Duvall B, Delahanty G et al. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem 2012; 55: 10551-10563.
84. Shroff EH, Eberlin LS, Dang VM, Gouw AM, Gabay M, Adam SJ et al. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proc Natl Acad Sci USA 2015; 112: 6539-6544.
85. Li J, Csibi A, Yang S, Hoffman GR, Li C, Zhang E et al. Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells. Proc Natl Acad Sci USA 2015; 112: E21-E29.
86. Ulanet DB, Couto K, Jha A, Choe S, Wang A, Woo HK et al. Mesenchymal phenotype predisposes lung cancer cells to impaired proliferation and redox stress in response to glutaminase inhibition. PLoS One 2014; 9: e115144.
87. Katt WP, Ramachandran S, Erickson JW, Cerione RA. Dibenzophenanthridines as inhibitors of glutaminase C and cancer cell proliferation. Mol Cancer Ther 2012; 11: 1269-1278.
88. Stalnecker CA, Ulrich SM, Li Y, Ramachandran S, McBrayer MK, DeBerardinis RJ et al. Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells. Proc Natl Acad Sci USA 2015; 112: 394-399.
89. Thornburg JM, Nelson KK, Clem BF, Lane AN, Arumugam S, Simmons A et al. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res 2008; 10: R84.
90. Korangath P, Teo WW, Sadik H, Han L, Mori N, Huijts CM et al. Targeting glutamine metabolism in breast cancer with aminooxyacetate. Clin Cancer Res 2015; 21: 3263-3273.
91. Ghesquiere B, Wong BW, Kuchnio A, Carmeliet P. Metabolism of stromal and immune cells in health and disease. Nature 2014; 511: 167-176.